Linked Life Data

17166379

Source:http://linkedlifedata.com/resource/pubmed/id/17166379

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2006-12-14
pubmed:abstractText
Animal experiment showed that recombinant human lymphotoxin-alpha derivate (rhLTalpha-Da) could inhibit tumor growth,activate immunity, sensitize tumors to chemotherapy, and has low toxicity in vivo. rhLTalpha-Da won't accumulate after multiple administrations. This study was to investigate pharmacokinetic profile of rhLTalpha-Da in tumor patients to provide reference for phase II clinical trail.
pubmed:language
chi
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1000-467X
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1524-8
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
[Clinical pharmacokinetic trial of intravenous injection of recombinant human lymphotoxin-alpha derivative].
pubmed:affiliation
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
pubmed:publicationType
Journal Article, English Abstract